Global Non-interventional Heart Failure Disease Registry
REPORT-HF
International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure
1 other identifier
observational
18,805
42 countries
331
Brief Summary
The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2014
Typical duration for all trials
331 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 23, 2014
CompletedFirst Submitted
Initial submission to the registry
October 13, 2015
CompletedFirst Posted
Study publicly available on registry
November 3, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2018
CompletedNovember 14, 2018
November 1, 2018
3.7 years
October 13, 2015
November 13, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Number of patients with different characteristics of heart faliure (HF) at hospitalization
From admission to discharge of the patient's index hospitalization (minimum 24 hours)
Percentage of patients who die during the index hospitalization
From admission to discharge of the patient's index hospitalization (minimum 24 hours)
Percentage of patients who die during the follow-up period post-discharge
up to 3 years
Percentage of patients who are re-hospitalized by primary re-hospitalization reason (Cardiovascular and non-Cardiovascular)
up to 3 years
Number of patients with different characteristics of post-discharge patient management
up to 3 years
Healthcare Resource Utilization assessed by number of patients with re-hospitalizations
up to 3 years
Secondary Outcomes (3)
Health-related Quality of life (HRQoL) based on patient reported data as measured by EQ-5D and the Kansas City Cardiomyopathy Questionnaire (KCCQ) questionnaires
up to 3 years
Caregiver burden based on Caregiver Burden Questionnaire -Heart Failure (CBQ-HF) and Work Productivity and Activity Impairment (WPAI) questionnaires
up to 3 years
Correlation ratio between practice patterns and outcomes
up to 3 years
Eligibility Criteria
Enrollment of adult patients hospitalized with a primary diagnosis of acute Heart Failure (HF), i.e. new-onset (first diagnosis) HF or decompensation of chronic HF
You may qualify if:
- Patients at least 18 years old, or older for those countries where the adult age is above 18 years of age, hospitalized with a primary diagnosis of acute heart failure.
You may not qualify if:
- Concomitant participation in any/a clinical trial with any investigational treatment (for any sponsor).
- \. Use of investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (346)
Novartis Investigative Site
San Diego, California, 92103, United States
Novartis Investigative Site
San Francisco, California, 94143-0780, United States
Novartis Investigative Site
Chicago, Illinois, 60611, United States
Novartis Investigative Site
Indianapolis, Indiana, 46202, United States
Novartis Investigative Site
Kansas City, Kansas, 66160, United States
Novartis Investigative Site
New Orleans, Louisiana, 70112, United States
Novartis Investigative Site
New Orleans, Louisiana, 70121, United States
Novartis Investigative Site
Detroit, Michigan, 48201, United States
Novartis Investigative Site
Detroit, Michigan, 48202, United States
Novartis Investigative Site
Jackson, Mississippi, 39216, United States
Novartis Investigative Site
New York, New York, 10029, United States
Novartis Investigative Site
Stony Brook, New York, 11794, United States
Novartis Investigative Site
Cincinnati, Ohio, 45267, United States
Novartis Investigative Site
Nashville, Tennessee, 37203, United States
Novartis Investigative Site
Dallas, Texas, 75390, United States
Novartis Investigative Site
Algiers, 16000, Algeria
Novartis Investigative Site
Algiers, 16040, Algeria
Novartis Investigative Site
Algiers, 16206, Algeria
Novartis Investigative Site
Oran, 31000, Algeria
Novartis Investigative Site
CABA, Buenos Aires, C1181ACH, Argentina
Novartis Investigative Site
CABA, Buenos Aires, C1210AAP, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires F.D., 1118, Argentina
Novartis Investigative Site
Coronel Suarez, Buenos Aires F.D., 7540, Argentina
Novartis Investigative Site
Resistencia, Chaco Province, H3500CDM, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, 2000, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, S2000DSV, Argentina
Novartis Investigative Site
Buenos Aires, C1094AAD, Argentina
Novartis Investigative Site
Buenos Aires, C1426EOB, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Corrientes, W3400AFT, Argentina
Novartis Investigative Site
Córdoba, X5000JHQ, Argentina
Novartis Investigative Site
Córdoba, X5000, Argentina
Novartis Investigative Site
Mendoza, M5500AAJ, Argentina
Novartis Investigative Site
Salta, 4000, Argentina
Novartis Investigative Site
Gosford, New South Wales, 2250, Australia
Novartis Investigative Site
Auchenflower, Queensland, 4066, Australia
Novartis Investigative Site
Greenslopes, Queensland, 4120, Australia
Novartis Investigative Site
Bedford Park, SA 5042, Australia
Novartis Investigative Site
Eisenstadt, 7000, Austria
Novartis Investigative Site
Linz, 4021, Austria
Novartis Investigative Site
Mödling, A-2340, Austria
Novartis Investigative Site
Vienna, A-1160, Austria
Novartis Investigative Site
Vienna, A-1220, Austria
Novartis Investigative Site
Fortaleza, Ceará, 60864-190, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, 30130-100, Brazil
Novartis Investigative Site
Curitiba, Paraná, 80010-030, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, 22280-020, Brazil
Novartis Investigative Site
Campinas, São Paulo, 13060-904, Brazil
Novartis Investigative Site
Tatuí, São Paulo, 18270-170, Brazil
Novartis Investigative Site
Curitiba, Brazil
Novartis Investigative Site
Recife, Brazil
Novartis Investigative Site
Rio de Janeiro, Brazil
Novartis Investigative Site
Sao Jose Do Rico Preto, Brazil
Novartis Investigative Site
Pleven, 5800, Bulgaria
Novartis Investigative Site
Plovdiv, 4002, Bulgaria
Novartis Investigative Site
Sofia, 1202, Bulgaria
Novartis Investigative Site
Sofia, 1527, Bulgaria
Novartis Investigative Site
Sofia, 1606, Bulgaria
Novartis Investigative Site
Varna, 9010, Bulgaria
Novartis Investigative Site
Edmonton, Alberta, T6G 2B7, Canada
Novartis Investigative Site
Vancouver, British Columbia, V6Z 1Y6, Canada
Novartis Investigative Site
Halifax, Nova Scotia, B3H 3A7, Canada
Novartis Investigative Site
Ottawa, Ontario, K1Y 4W7, Canada
Novartis Investigative Site
Sainte-Foy, Quebec, G1V 4G5, Canada
Novartis Investigative Site
San Miguel, Santiago Metropolitan, 8900000, Chile
Novartis Investigative Site
Concepción, Chile
Novartis Investigative Site
Santiago, Piso 1, Chile
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Beijing, Beijing Municipality, 100044, China
Novartis Investigative Site
Beijing, Beijing Municipality, 100191, China
Novartis Investigative Site
Fuzhou, Fujian, China
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
Novartis Investigative Site
Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site
Wuhan, Hubei, 430074, China
Novartis Investigative Site
Changsha, Hunan, 410005, China
Novartis Investigative Site
Changsha, Hunan, 410011, China
Novartis Investigative Site
Baotou, Inner Mongolia, 014040, China
Novartis Investigative Site
Changchun, Jilin, 130021, China
Novartis Investigative Site
Dalian, Liaoning, 116011, China
Novartis Investigative Site
Beijing, 100022, China
Novartis Investigative Site
Beijing, 100029, China
Novartis Investigative Site
Beijing, 100034, China
Novartis Investigative Site
Beijing, 100053, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, 510260, China
Novartis Investigative Site
Hangzhou, 310006, China
Novartis Investigative Site
Jinan, 250012, China
Novartis Investigative Site
Luoyang, 471000, China
Novartis Investigative Site
Shanghai, 200080, China
Novartis Investigative Site
Taiyuan, China
Novartis Investigative Site
Ürümqi, 830000, China
Novartis Investigative Site
Ürümqi, 830054, China
Novartis Investigative Site
Wuhan, 430022, China
Novartis Investigative Site
Xiamen, 361004, China
Novartis Investigative Site
Yangzhou, 225001, China
Novartis Investigative Site
Zhengzhou, 450003, China
Novartis Investigative Site
Zhengzhou, China
Novartis Investigative Site
Medellín, Antioquia, 0050010, Colombia
Novartis Investigative Site
Medellín, Antioquia, Colombia
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Bogotá, Cundinamarca, 110111, Colombia
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia
Novartis Investigative Site
Armenia, Colombia
Novartis Investigative Site
Bogotá, 00000, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Cali, Colombia
Novartis Investigative Site
Guayaquil, Guayas, Ecuador
Novartis Investigative Site
Quito, Pichincha, 1701, Ecuador
Novartis Investigative Site
Guayaquil, Ecuador
Novartis Investigative Site
Portoviejo, Ecuador
Novartis Investigative Site
Alexandria, 21411, Egypt
Novartis Investigative Site
Cairo, 11566, Egypt
Novartis Investigative Site
Cairo, Egypt
Novartis Investigative Site
El Menia, Upper Egypt, Egypt
Novartis Investigative Site
Suez Canal Region, 41111, Egypt
Novartis Investigative Site
Berlin, 13353, Germany
Novartis Investigative Site
Bonn, 53105, Germany
Novartis Investigative Site
Essen, 45356, Germany
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
Novartis Investigative Site
Göttingen, 37075, Germany
Novartis Investigative Site
Halle, 06120, Germany
Novartis Investigative Site
Hanover, 30625, Germany
Novartis Investigative Site
Heidelberg, 69120, Germany
Novartis Investigative Site
Homburg, 66421, Germany
Novartis Investigative Site
Ludwigshafen, 67063, Germany
Novartis Investigative Site
Lübeck, 23538, Germany
Novartis Investigative Site
Nuremberg, 90471, Germany
Novartis Investigative Site
Würzburg, 97078, Germany
Novartis Investigative Site
Athens, GR, 115 25, Greece
Novartis Investigative Site
Athens, GR, 115 27, Greece
Novartis Investigative Site
Athens, GR, 11527, Greece
Novartis Investigative Site
Thessaloniki, GR, 570 10, Greece
Novartis Investigative Site
Athens, 11526, Greece
Novartis Investigative Site
Athens, 54642, Greece
Novartis Investigative Site
Athens, GR 115 22, Greece
Novartis Investigative Site
Glyfada, 16675, Greece
Novartis Investigative Site
Ioannina, 45100, Greece
Novartis Investigative Site
Piraeus, 18454, Greece
Novartis Investigative Site
Thessaloniki, 54642, Greece
Novartis Investigative Site
Guatemala City, 01011, Guatemala
Novartis Investigative Site
Guatemala City, Guatemala
Novartis Investigative Site
Panjim, Goa, 403001, India
Novartis Investigative Site
Ahmedabad, Gujarat, 380 060, India
Novartis Investigative Site
Vadodara, Gujarat, 390022, India
Novartis Investigative Site
Gurgaon, Haryana, 122001, India
Novartis Investigative Site
Bangalore, Karnataka, 560 069, India
Novartis Investigative Site
Bangalore, Karnataka, 560099, India
Novartis Investigative Site
Manipal, Karnataka, 576104, India
Novartis Investigative Site
Nagpur, Maharashtra, 440008, India
Novartis Investigative Site
Pune, Maharashtra, 411 011, India
Novartis Investigative Site
Pune, Maharashtra, 411011, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110 060, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110017, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110070, India
Novartis Investigative Site
Amritsar, Punjab, 143004, India
Novartis Investigative Site
Ludhiana, Punjab, 141001, India
Novartis Investigative Site
Ludhiana, Punjab, 141008, India
Novartis Investigative Site
Chennai, Tamil Nadu, 600037, India
Novartis Investigative Site
Hyderabad, Telangana, 500034, India
Novartis Investigative Site
Hyderabad, Telangana, 500082, India
Novartis Investigative Site
Kolkata, West Bengal, 700 107, India
Novartis Investigative Site
Kolkata, West Bengal, 700099, India
Novartis Investigative Site
India, 560040, India
Novartis Investigative Site
Mumbai, 400053, India
Novartis Investigative Site
New Delhi, 110002, India
Novartis Investigative Site
New Delhi, 110025, India
Novartis Investigative Site
Tangerang, Banten, 15111, Indonesia
Novartis Investigative Site
East Jakarta, DKI Jakarta, 13630, Indonesia
Novartis Investigative Site
South Jakarta, DKI Jakarta, 12430, Indonesia
Novartis Investigative Site
West Jakarta, DKI Jakarta, 11420, Indonesia
Novartis Investigative Site
Surabaya, East Java, 60286, Indonesia
Novartis Investigative Site
Medan, North Sumatera, 20136, Indonesia
Novartis Investigative Site
Bandung, West Java, 40161, Indonesia
Novartis Investigative Site
Bekasi, West Java, 17144, Indonesia
Novartis Investigative Site
Padang, West Sumatra, 25127, Indonesia
Novartis Investigative Site
Jerusalem, 91031, Israel
Novartis Investigative Site
Jerusalem, 91240, Israel
Novartis Investigative Site
Kfar Saba, 4428164, Israel
Novartis Investigative Site
Nazareth, 16100, Israel
Novartis Investigative Site
Sefad, 13100, Israel
Novartis Investigative Site
Kitakyushu, Fukuoka, 802-8555, Japan
Novartis Investigative Site
Kure, Hiroshima, 737-0023, Japan
Novartis Investigative Site
Sakaidechō, Kagawa-ken, 762-0007, Japan
Novartis Investigative Site
Kita-ku, Okayama-ken, 7000084, Japan
Novartis Investigative Site
Hirakata, Osaka, 573-0153, Japan
Novartis Investigative Site
Chiyoda-ku, Tokyo, 101-8643, Japan
Novartis Investigative Site
Nagasaki, 850-8555, Japan
Novartis Investigative Site
Amman, 11121, Jordan
Novartis Investigative Site
Amman, 11196, Jordan
Novartis Investigative Site
Amman, 11942, Jordan
Novartis Investigative Site
Amman, Jordan
Novartis Investigative Site
Irbid, 22110, Jordan
Novartis Investigative Site
El Chouf, LBN, Lebanon
Novartis Investigative Site
Beirut, 1107 2020, Lebanon
Novartis Investigative Site
Beirut, 6301, Lebanon
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
Byblos, Lebanon
Novartis Investigative Site
Saida, 652, Lebanon
Novartis Investigative Site
Alor Star, Kedah, 05460, Malaysia
Novartis Investigative Site
Kota Bharu, Kelantan, 16150, Malaysia
Novartis Investigative Site
Pulau Pinang, Pulau Pinang, 10990, Malaysia
Novartis Investigative Site
Johor Bahru, 80100, Malaysia
Novartis Investigative Site
Kuala Lumpur, 50586, Malaysia
Novartis Investigative Site
Mexico City, Mexico City, 03100, Mexico
Novartis Investigative Site
Mexico City, Mexico City, 06090, Mexico
Novartis Investigative Site
Mexico City, Mexico City, 14080, Mexico
Novartis Investigative Site
Culiacán, Sinaloa SN, 80230, Mexico
Novartis Investigative Site
Aguascalientes, 20230, Mexico
Novartis Investigative Site
San Luis Potosí City, 78213, Mexico
Novartis Investigative Site
San Luis Potosí City, 78240, Mexico
Novartis Investigative Site
Xalapa, 91020, Mexico
Novartis Investigative Site
Xalapa, 91193, Mexico
Novartis Investigative Site
Casablanca, Morocco
Novartis Investigative Site
Marrakesh, 40 000, Morocco
Novartis Investigative Site
Rabat, 10 000, Morocco
Novartis Investigative Site
Amsterdam, 1034CS, Netherlands
Novartis Investigative Site
Groningen, 9713 GZ, Netherlands
Novartis Investigative Site
Leiderdorp, NL-2353 GA, Netherlands
Novartis Investigative Site
Sneek, 8601ZK, Netherlands
Novartis Investigative Site
Venlo, 5912 BL, Netherlands
Novartis Investigative Site
Zwolle, 8025 AB, Netherlands
Novartis Investigative Site
Hønefoss, 3501, Norway
Novartis Investigative Site
Oslo, 370, Norway
Novartis Investigative Site
Skien, NO-3710, Norway
Novartis Investigative Site
San Jose de David, Provincia de Panamá, Panama
Novartis Investigative Site
Panama City, Panama
Novartis Investigative Site
Baguio City, Baguio, 2600, Philippines
Novartis Investigative Site
Cagayan de Oro City, Cagayan Valley, 9000, Philippines
Novartis Investigative Site
Cebu City, Cebu, 6000, Philippines
Novartis Investigative Site
Davao City, Davao Region, 8000, Philippines
Novartis Investigative Site
Quezon City, Manila, 1100, Philippines
Novartis Investigative Site
Manila, National Capital Region, 1000, Philippines
Novartis Investigative Site
Angeles City, Pampanga, 2009, Philippines
Novartis Investigative Site
Cluj-Napoca, Napoca, 400006, Romania
Novartis Investigative Site
Bucharest, 022322, Romania
Novartis Investigative Site
Bucharest, 030 171, Romania
Novartis Investigative Site
Buzău, 120140, Romania
Novartis Investigative Site
Cluj-Napoca, 400006, Romania
Novartis Investigative Site
Focşani, 620034, Romania
Novartis Investigative Site
Lasi, 700075, Romania
Novartis Investigative Site
Timișoara, 300054, Romania
Novartis Investigative Site
Kazan', 420033, Russia
Novartis Investigative Site
Kemerovo, 654005, Russia
Novartis Investigative Site
Krasnodar, 350086, Russia
Novartis Investigative Site
Moscow, 117292, Russia
Novartis Investigative Site
Moscow, 127473, Russia
Novartis Investigative Site
Novosibirsk, 630091, Russia
Novartis Investigative Site
Ryazan, 390026, Russia
Novartis Investigative Site
S-Petersburg, 194354, Russia
Novartis Investigative Site
Saint Petersburg, 191015, Russia
Novartis Investigative Site
Saint Petersburg, 194044, Russia
Novartis Investigative Site
Saint Petersburg, 197341, Russia
Novartis Investigative Site
Saratov, 410004, Russia
Novartis Investigative Site
Saratov, 410017, Russia
Novartis Investigative Site
Stavropol, 355030, Russia
Novartis Investigative Site
Tyumen, 625023, Russia
Novartis Investigative Site
Ulyanovsk, 432057, Russia
Novartis Investigative Site
Vladivostok, 690002, Russia
Novartis Investigative Site
Volgograd, 400026, Russia
Novartis Investigative Site
Al Ahsa, Saudi Arabia
Novartis Investigative Site
Dammam, 15215, Saudi Arabia
Novartis Investigative Site
Dammam, 31463, Saudi Arabia
Novartis Investigative Site
Khamis Mushait, 62413, Saudi Arabia
Novartis Investigative Site
Riyadh, 3643, Saudi Arabia
Novartis Investigative Site
Durban, KwaZulu-Natal, 4052, South Africa
Novartis Investigative Site
Bloemfontein, 9301, South Africa
Novartis Investigative Site
Cape Town, 7405, South Africa
Novartis Investigative Site
Cape Town, 7505, South Africa
Novartis Investigative Site
Rivonia, 2128, South Africa
Novartis Investigative Site
Gyeonggi-do, Bucheon-si, 422-711, South Korea
Novartis Investigative Site
Wŏnju, Gangwon-do, 220-701, South Korea
Novartis Investigative Site
Daejeon, Korea, 301-721, South Korea
Novartis Investigative Site
Cheongju-si, North Chungcheong, 28644, South Korea
Novartis Investigative Site
Busan, 612-896, South Korea
Novartis Investigative Site
Incheon, 403-720, South Korea
Novartis Investigative Site
Pusan, 614-735, South Korea
Novartis Investigative Site
Seoul, 07061, South Korea
Novartis Investigative Site
Seoul, 136-705, South Korea
Novartis Investigative Site
Suwon, 16247, South Korea
Novartis Investigative Site
Taegu, 700 -721, South Korea
Novartis Investigative Site
Mallorca, Balearic Islands, 07198, Spain
Novartis Investigative Site
Barakaldo, Basque Country, 48903, Spain
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
Novartis Investigative Site
Tarragona, Catalonia, 43005, Spain
Novartis Investigative Site
Mérida, Extremadura, 06800, Spain
Novartis Investigative Site
Las Palmas de Gran Canaria, Las Palmas de G.C, 35020, Spain
Novartis Investigative Site
Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site
Alicante, Valencia, 03010, Spain
Novartis Investigative Site
Barcelona, 08041, Spain
Novartis Investigative Site
Córdoba, Spain
Novartis Investigative Site
León, 24080, Spain
Novartis Investigative Site
Murcia, 30008, Spain
Novartis Investigative Site
Gothenburg, 416 85, Sweden
Novartis Investigative Site
Helsingborg, 252 20, Sweden
Novartis Investigative Site
Karlshamn, 37480, Sweden
Novartis Investigative Site
Linköping, 581 85, Sweden
Novartis Investigative Site
Malmo, 205 20, Sweden
Novartis Investigative Site
Trollhättan, 46173, Sweden
Novartis Investigative Site
Basel, 4031, Switzerland
Novartis Investigative Site
Bruderholz, 4101, Switzerland
Novartis Investigative Site
Zurich, 8032, Switzerland
Novartis Investigative Site
Linkou District, 33305, Taiwan
Novartis Investigative Site
Taichung, 40705, Taiwan
Novartis Investigative Site
Tainan, 70421, Taiwan
Novartis Investigative Site
Taipei, 10002, Taiwan
Novartis Investigative Site
Taipei, 110, Taiwan
Novartis Investigative Site
Taipei, 11217, Taiwan
Novartis Investigative Site
Muang, Muang, 65000, Thailand
Novartis Investigative Site
Muang, Thailand, 12120, Thailand
Novartis Investigative Site
Muang, Thailand, 30000, Thailand
Novartis Investigative Site
Khon Kaen, THA, 40002, Thailand
Novartis Investigative Site
Bangkok, 10310, Thailand
Novartis Investigative Site
Bangkok, 10400, Thailand
Novartis Investigative Site
Chiang Mai, 50200, Thailand
Novartis Investigative Site
Monastir, 5000, Tunisia
Novartis Investigative Site
Sousse, 4011, Tunisia
Novartis Investigative Site
Tunis, 1006, Tunisia
Novartis Investigative Site
Tunis, 1007, Tunisia
Novartis Investigative Site
Tunis, 1008, Tunisia
Novartis Investigative Site
Pendik / Istanbul, Turkey, 34899, Turkey (Türkiye)
Novartis Investigative Site
Ankara, 06100, Turkey (Türkiye)
Novartis Investigative Site
Ankara, 06590, Turkey (Türkiye)
Novartis Investigative Site
Bursa, 16059, Turkey (Türkiye)
Novartis Investigative Site
Bursa, Turkey (Türkiye)
Novartis Investigative Site
Diskapi / Ankara, 06110, Turkey (Türkiye)
Novartis Investigative Site
Haydarpasa/Istanbul, 34668, Turkey (Türkiye)
Novartis Investigative Site
Istanbul, 34093, Turkey (Türkiye)
Novartis Investigative Site
Meselik / Eskisehir, 26480, Turkey (Türkiye)
Novartis Investigative Site
Sivas, 58140, Turkey (Türkiye)
Novartis Investigative Site
Abu Dhabi, 51900, United Arab Emirates
Novartis Investigative Site
Al Ain City, United Arab Emirates
Novartis Investigative Site
Dubai, 7272, United Arab Emirates
Novartis Investigative Site
Dubai, United Arab Emirates
Novartis Investigative Site
Edgbaston, Birmingham, B15 2WB, United Kingdom
Novartis Investigative Site
Stockton-on-Tees, Cleveland, TS19 8PE, United Kingdom
Novartis Investigative Site
Bradford, West Yorkshire, BD9 6RJ, United Kingdom
Novartis Investigative Site
Chesterfield, Yorkshire, S44 5BL, United Kingdom
Novartis Investigative Site
Herts, Yorkshire, SG1 4AB, United Kingdom
Novartis Investigative Site
Chesterfield, BS1 3NU, United Kingdom
Novartis Investigative Site
Telford, TF1 6TF, United Kingdom
Novartis Investigative Site
Uxbridge, UB8 3NN, United Kingdom
Novartis Investigative Site
Wakefield, WF1 4DG, United Kingdom
Novartis Investigative Site
York, YO31 8HE, United Kingdom
Novartis Investigative Site
Ho Chi Minh City, District 7, Vietnam
Novartis Investigative Site
Ho Chi Minh City, Vietnam
Related Publications (4)
Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, Angermann CE, Ertl G, Dahlstrom U, Hu D, Dickstein K, Perrone SV, Ghadanfar M, Bermann G, Noe A, Schweizer A, Maier T, Gheorghiade M. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May;17(5):527-33. doi: 10.1002/ejhf.262. Epub 2015 Mar 10.
PMID: 25754836BACKGROUNDTay WT, Teng TK, Ouwerkerk W, Cleland JGF, Collins SP, Angermann CE, Dickstein K, Dahlstrom U, Schweizer A, Obergfell A, Yiu KH, Ghadanfar M, Hassanein M, Ren QW, Gu WL, Ertl G, Perrone SV, Filippatos G, Lam CSP, Tromp J. Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registry. Eur J Heart Fail. 2025 Oct 1. doi: 10.1002/ejhf.70056. Online ahead of print.
PMID: 41031485DERIVEDChyou JY, Tay WT, Tromp J, Ouwerkerk W, Yiu KH, Cleland JGF, Collins SP, Angermann CE, Ertl G, Dahlstrom U, Dickstein K, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Filippatos G, Lam CSP. Prognostic Implications and Global Perspectives of Atrial Fibrillation in Patients Hospitalized for Heart Failure. JACC Heart Fail. 2025 Mar;13(3):453-464. doi: 10.1016/j.jchf.2024.11.009. Epub 2025 Feb 5.
PMID: 39918534DERIVEDOuwerkerk W, Tromp J, Cleland JGF, Angermann CE, Dahlstrom U, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Dickstein K, Filippatos G, Collins SP, Lam CSP. Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. Eur J Heart Fail. 2023 Jan;25(1):43-51. doi: 10.1002/ejhf.2708. Epub 2022 Nov 23.
PMID: 36196060DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 13, 2015
First Posted
November 3, 2015
Study Start
July 23, 2014
Primary Completion
March 31, 2018
Study Completion
March 31, 2018
Last Updated
November 14, 2018
Record last verified: 2018-11